You are here: Industry Insights > Lilly

News List

AbCellera reports bamlanivimab’s potency against SARS-CoV-2 in study pharmaceutical-technology
April 06, 2021
AbCellera (ABCL) has reported that bamlanivimab (LY-CoV555) demonstrated high potency in neutralising SARS-CoV-2 by uniquely binding both up and down confirmations of the spike receptor-binding domain (RBD) in preclinical study.
Lilly, Vir and GSK report positive data from Covid-19 antibody trial pharmaceutical-technology
March 30, 2021
Eli Lilly and Company, Vir Biotechnology and GlaxoSmithKline (GSK) have reported topline data from the expanded Phase II BLAZE-4 trial of bamlanivimab (LY-CoV555) co-administered with VIR-7831 (GSK4182136) in low-risk adult patients with mild to ...
Eli Lilly Stops Distribution of Bamlanivimab as COVID-19 Treatment americanpharmaceuticalreview
March 29, 2021
The US government in coordination with Eli Lilly said it will no longer distribute the COVID-19 monoclonal antibody therapy bamlanivimab for use on its own.
FDA panel votes against Pfizer’s tanezumab for osteoarthritis pain pharmaceutical-technology
March 29, 2021
A joint FDA advisory committee has rejected a risk mitigation proposal for Pfizer and Eli Lilly’s osteoarthritis (OA) drug tanezumab, concluding that the drug’s safety risk to patients is too high.
Lilly’s mirikizumab hits primary endpoint in ulcerative colitis study pharmatimes
March 18, 2021
Eli Lilly’s anti-IL-23p19 monoclonal antibody (mAb) mirikizumab has met the primary endpoint and all key secondary endpoints in a Phase III ulcerative colitis (UC) study.
Lilly, Biolojic to develop antibody therapies for diabetes treatment pharmaceutical-business-review
March 15, 2021
Eli Lilly and Company has signed a research collaboration and license agreement with Biolojic Design to discover and develop therapies for diabetes treatment.
MHRA authorises Lilly’s RET inhibitor Retsevmo pharmatimes
March 11, 2021
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Eli Lilly’s Retsevmo a conditional marketing authorisation for the treatment of RET fusion-positive advanced lung cancer and thyroid cancer.
Lilly’s bamlanivimab plus etesevimab cut death, hospitalisations for early COVID-19 in Phase III trial expresspharma
March 11, 2021
Results support use of bamlanivimab 700 mg and etesevimab 1400 mg, the dose authorised in the US and several other countries.
Jubilant HollisterStier, Eli Lilly Enter COVID-19 Treatment Collaboration contractpharma
March 10, 2021
The CMO signs manufacturing agreement with Lilly for COVID-19 therapeutic Bamlanivimab.
EMA concludes review of Lilly’s COVID-19 antibody therapies europeanpharmaceuticalreview
March 09, 2021
The human medicines committee decided that there was significant evidence to endorse the use of a combination of bamlanivimab and etesevimab in outpatients at high risk of severe COVID-19.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page